Dosisjustering bør imidlertid ikke generelt være nødvendig hos patienter, der får ketoconazol.
Plasma exposure (AUC and Cmax) to valdecoxib was increased (38% and 24%, respectively) when co- administered with ketoconazole (CYP3A4 inhibitor), however, a dosage adjustment should not generally be necessary for patients receiving ketoconazole.